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Background and Purpose: Cerebral microbleeds are an intracerebral microangiopathy
with bleeding tendency found in intracerebral hemorrhage patients. However, studies
about cerebral microbleed effects on the prognosis of hypertensive intracerebral
hemorrhage patients are rare. We performed a prospective study to discuss not only the
risk factors of cerebral microbleed incidence in hypertensive intracerebral hemorrhage
patients but also the relevance of cerebral microbleeds with silent brain infarction,
hemorrhage and prognosis.
Methods: This study enrolled 100 patients diagnosed with hypertensive intracerebral
hemorrhage within 3 days after onset. Magnetic resonance imaging including
susceptibility-weighted imaging and diffusion-weighted imaging (DWI) were utilized to
examine patients on the fifth day after onset. Regular follow-ups were performed to
examine the following clinical cerebrovascular events and vascular deaths in 1 year.
Results: Cerebral microbleeds were observed in 55 (55%) patients. Multiple
logistic regression analysis showed that over-aging, elevation of serum creatinine,
and leukoaraiosis were independently associated with cerebral microbleeds. In
addition, higher silent brain infarction prevalence was observed in patients with
cerebral microbleeds. In contrast, none of the cerebral microbleed patients exhibited
cerebral microbleeds ≥5, which is an independent risk factor of poor 3-month
neurological function recovery. During the 1-year follow-up, 14 subjects presented
clinical cerebrovascular events or vascular death. The Cox proportional hazards model
implicated that atrial fibrillation, cerebral microbleeds ≥5 and silent brain infarction were
independent predictive factors for these events.
Conclusions: Over-aging combined with an elevation of serum creatinine and
leukoaraiosis were independent risk factors of cerebral microbleeds. Patients with
cerebral microbleeds were more likely to exhibit silent brain infarction. Poor recovery of
3-month neurological function was observed in hypertensive intracerebral hemorrhage
patients with cerebral microbleeds ≥5. Cerebral microbleeds ≥5 or silent brain infarction
might also indicate an elevated risk of future cerebrovascular events and vascular death.
Keywords: cerebral microbleeds, silent brain infarction, hypertension, intracerebral hemorrhage, magnetic
resonance imaging
Yang et al. Microbleeds in Intracerebral Hemorrhage Patients
INTRODUCTION
Spontaneous intracerebral hemorrhage occurs at an incidence
of 10∼30% of first-ever strokes, and 30∼55% of patients reach
mortality in 1 month (Balami and Buchan, 2012; Tsai et al.,
2013). However, hypertensive intracerebral hemorrhage (HICH)
occurs in 70∼80% of spontaneous intracerebral hemorrhages
(ICHs). In addition, the incidence of CMBs in ICH patients
can reach 50∼80% (Greenberg et al., 2004; Jeong et al., 2004;
Imaizumi et al., 2008), which is much higher than the 15∼35%
observed in cerebral infarction patients (Fiehler et al., 2007;
Yamada et al., 2012). CMBs are the haemosiderin exuded from
cerebral small vessels and precipitated around small vessels.
The characteristics of CMBs in gradient echo T2∗-weighted
imaging (GRE T2∗WI) or susceptibility-weighted imaging (SWI)
are small circumscribed round foci and low signals (Greenberg
et al., 2009b). Furthermore, CMBs occurring in the deep brain are
mostly related to small vessel diseases induced by atherosclerosis
or hypertension, while CMBs focused in lobes are more likely
caused by cerebral amyloid angiopathy (Fazekas et al., 1999;
Knudsen et al., 2001).
Unfortunately, few studies targeting the effect of CMBs
on the prognosis of HICH patients have been performed.
Moreover, the subjects are mainly acute cerebral infarction
patients (Dannenberg et al., 2014; Gratz et al., 2014; Turc et al.,
2015; Yan et al., 2015). Nevertheless, an increasing number of
scholars have realized these challenges and are working to resolve
them. Due to the report indicating that the risks of disabling
and fatal strokes could increase in acute cerebral infarction
patients or transient ischaemic attack with CMBs (Boulanger
et al., 2006), we aimed to determine whether CMBs could
increase these risks in HICH patients. Previous studies have
revealed that the GRE T2∗WI sequence is broadly used in CMBs
research studies (Lee et al., 2006; Kang et al., 2012; Turc et al.,
2015). However, recent studies have indicated that the SWI
sequence demonstrated a better detection rate than the GRE
T2∗WI sequence (Guo et al., 2013). Thus, we utilized SWI to
detect CMBs to determine whether CMBs could indicate a higher
probability for the incidence of clinical cerebrovascular events or
vascular deaths in the following first year, which may clinically
benefit HICH patients.
METHODS
Patients
We prospectively and continuously recruited acute intracerebral
hemorrhage patients from August 2012 to April 2015 in the
Department of Neurology of the Affiliated Rui Jin Hospital of
Shanghai Jiao Tong University and Affiliated Min Hang Hospital
of Fudan University. Regular follow-ups were performed during
the following year after onset. The inclusion criteria were as
follows: (1) age over 35 years; (2) diagnosed as acute intracerebral
hemorrhage in 3 days by CT after onset; and (3) possessing
hypertension history. The definition of hypertension was as
follows: (1) with hypertension history or (2) with hypertension
in three separate sphygmomanometer measurements during the
admission period (systolic pressure ≥140 mmHg or diastolic
pressure ≥90 mmHg) combined with evidence of end-stage
organ injury (e.g., hypertensive retinopathy, hypertrophy or
enlargement of the left ventricle). The exclusion criteria were as
follows: ICH secondary to cerebral tumor; with the possibility
to be intracranial hemorrhage related with cerebral amyloid
angiopathy (Knudsen et al., 2001); ICH due to abnormal brain
structure; moyamoya disease; intracranial ruptured aneurysms;
hemorrhage caused by craniocerebral trauma; haematemesis or
taking an anticoagulant drug; with contraindications for MRI,
pregnant women, or subjects who refused to participate in the
study. The time of disease onset was recorded as the last time
when the patients were evaluated to be without stroke symptoms.
During the admission period, all of the patients received proper
medical treatments and supportive care.
This study was approved by the ethics committee of Rui Jin
Hospital, which is affiliated with Shanghai Jiao Tong University
School of Medicine. All patients or their legal guardian signed the
written consent form.
General clinical data, laboratory data and imaging data
of the patients were collected as shown in Table 1. The
National Institutes of Health stroke scale (NIHSS) and Glasgow
Coma Scale (GCS) were selected to evaluate the severity of
the neurological functional impairment of the patients upon
admission.
Imaging Analysis
A cranial CT was performed on all patients on the third day after
onset, and a cranial MRI was performed on the fifth day. The
GE Signa HDxT 3.0 T superconductor MRI system was selected
for MRI examination with eight-channel phased-array head coil
utilized for scanning. All patients were first examined with axial
T1WI, T2WI and then with diffusion-weighted imaging (DWI)
and SWI. The DWI parameters were as follows: single shot
echo planar imaging technique; TR/TE = 10,000 ms/Minimum;
contiguous layer thickness as 5 mm; spacing as 1 mm; FOV =
230 × 230 mm; matrix as 128 × 64, 128 × 128, and 128 × 256
separately; dispersion sensitivity coefficient (b-value) as 0, 1,000
s/mm2 separately. The DWI graphs were imported into the GE
workstation, and the apparent diffusion coefficient (ADC) graphs
could then be calculated using the Functool software. The SWI
parameters were as follows: TR/TE = 36/45 ms, flip angle as
20◦; contiguous slice thickness as 2 mm; matrix as 448 × 384;
NEX = 0.75. All scanning examinations in different medical
centers were operated by a skilled radiological technician. Two
senior radiologists randomly read and recorded the graphic
information. When a conflict occurred, a decision was made
upon a final consensus.
The hemorrhage and CMB locations were classified according
to anatomical division, including the lobes, basal ganglia,
thalamus, brainstem, and cerebellum. The formula used to
calculate the cerebral haematoma volumes was the following:
(1/2)∗A∗B∗C, in which A referred to the longest diameter of
haematoma volumes in the CT axial image, B indicated the
short diameter perpendicular to the longest diameter, and C
was defined as the product of layers multiplied by contiguous
layer thickness (Kazui et al., 1997). Silent brain infarction (SBI)
was defined as dispersion abnormal signals more than 20mm
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TABLE 1 | Univariate analysis of patients with or without CMBs.
CMB not
present n = 45
CMBs present
n = 55
P-value
Age, mean (SD) 58.0 ± 11.0 62.7 ± 13.5 0.062
Sex, male (%) 28 (62.2%) 37 (67.3%) 0.598
RISK FACTORS, YES (%)
Diabetes mellitus 6 (13.3%) 11 (20.0%) 0.377
Hyperlipidemia 28 (62.2%) 32 (58.2%) 0.682
Current smoking 14 (31.1%) 19 (34.5%) 0.716
Drinking 8 (17.8%) 10 (18.2%) 0.958
Atrial fibrillation 1 (2.2%) 3 (5.5%) 0.758
Prior ischaemic stroke 3 (6.7%) 6 (10.9%) 0.699
MEDICATIONS, YES (%)
Antiplatelet use prior to ICH 3 (6.7%) 13 (23.6%) 0.021
Antidiabetics use prior to ICH 4 (8.9%) 7 (12.7%) 0.773
ADMISSION LABORATORY DATA (IQR)
TG, mmol/L 1.5 (1.2–2.2) 1.5 (1.1–2.0) 0.763
Cholesterol, mmol/L 4.8 (4.0–5.5) 4.7 (4.1–5.4) 0.876
H-DLC, mmol/L 1.1 (0.9–1.3) 1.1 (0.9–1.4) 0.975
L-DLC, mmol/L 3.1 (2.3–3.6) 3.0 (2.5–3.6) 0.771
BUN, mmol/L 4.3 (3.3–5.4) 5.1 (4.1–6.0) 0.038
Cr, umol/L 63.0 (47.5–70.5) 65.0 (54.0–79.0) 0.040
Homocysteine, umol/L 12.1 (9.5–15.8) 16.3 (12.2–22.1) 0.001
Glucose, mmol/L 5.1 (4.6–6.7) 5.0 (4.4–6.6) 0.540
BLOOD PRESSURE VARIABLES (MMHG)
Initial SBP at ER 150.07 ± 21.48 156.65 ± 28.38 0.202
Initial DBP at ER 88.73 ± 11.63 90.07 ± 15.49 0.639
Mean arterial pressure at ER 109.18 ± 14.09 112.27 ± 18.57 0.360
NIHSS SCORE, MEDIAN (IQR)
Baseline 4 (2–6.5) 3 (2–5) 0.057
Discharge 4 (2–5) 3 (2–4) 0.181
Baseline-Discharge 0 (0–2) 1 (0–1) 0.665
GCS 15 (14.5–15.0) 15.0 (15.0–15.0) 0.181
RADIOLOGIC DATA
ICH location
Basal ganglia 25 (55.56%) 27 (49.09%)
Thalamus 7 (15.56%) 15 (27.27%)
Pons 3 (6.67%) 3 (5.45%)
Cerebellum 1 (2.22%) 3 (5.45%)
Lobar 9 (20%) 7 (12.73%)
Leukoaraiosis 16 (35.6%) 34 (61.8%) 0.009
Silent brain infarction 1 (2.2%) 10 (18.2%) 0.027
CMBs, cerebral microbleeds; IQR, interquartile range; TG, triglyceride; BUN, blood urea
nitrogen; Cr, creatinine; DBP, diastolic blood pressure; SBP, systolic blood pressure;
NIHSS, NIH Stroke Scale; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage.
away from the original haematoma area manifesting as low-
signal foci in ADC graphs (Wardlaw et al., 2013a). The definition
of silent was no new symptoms, such as abnormal sensation
and limb weakness or deterioration of the original neurological
system function occurring in the patients. However, CMBs were
defined as 2∼5mm-diameter round or circular reducing signal
shadows and circumscribed round foci with no surrounding
oedema (Greenberg et al., 2009a; Wardlaw et al., 2013b). In
addition, the signals caused by calcification, perivascular space,
small vein, and other factors were excluded.We could distinguish
CMBs from HICH using head MRI. First, CMBs were negative
in typical T1WI and T2WI sequences and round or oval even
at low signal sites in GRE-T2∗WI and SWI sequences with no
surrounding oedema zone (Greenberg et al., 2009a). However,
acute phase cerebral hemorrhage induced an equivalent signal
in T1WI and a slightly low signal in T2WI, while sub-acute or
chronic haematoma showed a high signal in both the T1WI or
T2WI. Second, CMBs sites were round or oval with a diameter of
2∼5mm, which were significantly different with the morphology
and volume of cerebral hemorrhage haematoma. According to
previous research studies, the number of CMBs were then sorted
into 4 levels: level 1 with 0 CMBs, level 2 with 1 CMB, level 3 with
2∼4 CMBs, and level 4 with more than 5 CMBs (Dannenberg
et al., 2014).
Clinical Follow-Ups
All patients were provided with proper post-discharge drug
therapy, including regular treatments, such as anti-hypertension,
glucose lowering, and serum lipid regulation. Neurological
physicians supplied the outpatient service and telephone follow-
ups to the patients or their relatives every 3 months over
the next year to obtain the recovery information of the post-
discharge patients and to determine whether any other clinical
cerebrovascular events or deaths occurred. The Modified Rankin
Scale (mRS) was utilized to evaluate neurological functional
recovery in the 3months and 1 year.We defined well prognosis as
mRS ≤2, while bad prognosis was defined when mRS >2 (Turc
et al., 2015). However, the clinical cerebrovascular events were
defined as the onset of diseases, which forced the patients to
go to hospital and undergo image examinations and treatments
of the nervous system (Kang et al., 2012). Vascular deaths were
defined as sudden death (including cardiac death, death caused
by recurrent cerebral infarction or ICH) but not related to
tumors, infection or suicide.
Data Analysis
Statistical analysis was performed using SPSS18.0 (SPSS Inc.,
Chicago, IL, USA) and GraphPad Prism 5.0 (GraphPad Software,
San Diego, CA, USA). Baseline clinical data and imaging data
were compared with or without CMBs. Continuous variables
were expressed as the mean ± SD or median (interquartile
range). Comparisons were evaluated using Student’s t-test or
the Mann Whitney U-test according to whether the data fit
a normal distribution. However, continuous variables were
expressed the percentage and were compared using χ2 or Fisher’s
exact tests. Backward stepwise multiple logistic regression
analysis was performed to analyse the relationship between
neurological functional recovery in 3 months after onset and
CMB number, as well as the CMB independent risk factors.
The Spearman rank correlation coefficient was determined to
assess the relationship between CMB number and haematoma
volume. The Cox proportional hazards model was established
to calculate the risk ratio of clinical cerebrovascular events
or vascular deaths in the 1-year follow-up. Corrections of
the model included the age, gender, atrial fibrillation, stroke
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history, haematoma volume, CMBs, SBI, leukoaraiosis, and
other factors. P < 0.05 was considered a statistically significant
difference.
RESULTS
General Data
Of 130 patients screened, 30 among them were excluded for the
reasons below: 11 patients for more than 3 days from onset, 8
for cerebral amyloid angiopathy based on the Boston diagnostic
criteria, 5 for trauma, 3 for tumors, 2 for rejection of participation
and 1 for the contraindication of MRI. Thus, a total of 100
patients participated in this study. Fifty-five patients (55%) were
diagnosed with CMBs, consisting of 37 males (67.3%) and 18
females (32.7%) with an average age of 63 ± 14. Moreover, 45
patients (45%) had noCMBs, and 28males (62.2%) demonstrated
an average age of 58 ± 11. All subjects exhibited hypertension
histories ranging from 0.3 to 30 years. The time between disease
onset and CT examination ranged from below 24 h (85 patients),
24∼48 h (11), and 48∼72 h (4). Cranial MRI was provided to
the patients on the fifth day after onset. Ninety-eight patients
received the follow-up, and during the 3 months from onset, 82
patients had good prognosis (83.7%).
Affecting Factors of CMBs
The comparisons at baseline between patients with or without
CMBs are shown in Table 1. Compared with patients without
CMBs, positive patients demonstrated increased blood urea
nitrogen, creatinine, homocysteine levels, and the prevalence of
leukoaraiosis (P = 0.038, P = 0.04, P = 0.001, P = 0.009).
When establishing backward stepwisemultiple logistic regression
models, it was also found that patients who were of old age (odds
ratio [OR] = 1.04; 95% confidence interval [CI], 1.00–1.08; P =
0.039) or had increased serum creatinine levels (OR = 1.03; 95%
CI, 1.00–1.05; P = 0.011) or leukoaraiosis (OR = 2.97; 95% CI,
1.28–6.89; P = 0.016) were more likely to suffer from CMBs.
CMBs and SBI
Eleven HICH (11%) patients demonstrated SBI in DWI
sequences with a total SBI number of 14. SBI was round or
ovoid, and all of the foci were very small (diameters ranging
from 2.5 to 14.4 mm). In addition, SBI was not relevant with
the clinical symptoms, signs, and disease progression. Among the
SBI patients, seven occurred in the basal ganglia area, while three
occurred in the lobes, and 1 was found in the brainstem. Among
the SBI patients, 10 had CMBs (90.1%), and these patients with
CMBs also had a predisposition for SBI (18.2 vs. 2.2%, P= 0.027).
CMBs and ICH
In 55 patients with CMBs, we found a total of 431 CMBs, of which
287 (66.6%) were located in the basal ganglia and thalamus, 92
(21.3%) were located in the subcortical area, 38 (8.8%) were
located in the brainstem, and 14 (3.2%) were located in the
cerebellum.
In patients with lobe hemorrhage, higher haematoma volumes
were discovered in patients with CMBs (15.60 ± 6.93 vs. 7.33
± 3.39mL; P = 0.002), and a positive correlation was observed
between CMB number and haematoma volume (r = 0.677, P
= 0.006). However, in the patients with deep brain hemorrhage
(basal ganglia and thalamus), higher haematoma volumes were
found in patients without CMBs (4.37 ± 4.33mL vs. 10.03 ±
10.38mL; p = 0.005) with a negative correlation between the
CMB number and haematoma volumes (r = −0.243, P= 0.015).
For infratentorial hemorrhage patients, no significant differences
in haematoma volumes were observed between the groups with
or without CMBs (Figure 1).
CMBs and Prognosis
The ratio of poor 3-month prognosis in HICH patients with
CMBs was higher than that in patients without CMBs (81.3
vs. 51.2%, P = 0.026). Univariate analysis revealed a poorer
prognosis in patients with CMBs ≥5 than patients without
CMBs (30.8 vs. 7.0%; OR = 11.28; 95% CI, 2.72–46.76; P <
0.001). Backward stepwise multiple logistic regression analysis
also indicated that CMBs ≥5 were one of the independent risk
factors for poor prognosis in 3 months (OR = 27.09; 95% CI,
3.75–195.60; P = 0.001, Table 2).
Fourteen patients presented with cerebrovascular events or
deaths during the 1 year follow-up, which consisted of nine
cerebral infarctions, one recurrent cerebral hemorrhage and four
vascular deaths (Figure 2). In those 14 patients, 6 were with
SBI (42.86%), and 12 were with CMBs (85.71%, 11 with CMBs
≥5). Moreover, in these 12 patients, 7 presented with recurrent
cerebral infarction, and 1 demonstrated recurrent cerebral
hemorrhage. The number of recurrent cerebral infarction
patients with both SBI and CMBs was 5. Patients with CMBs
had a higher mRS score in the first year than those without
CMBs (Figure 3). The multifactorial Cox proportion analysis
model showed that atrial fibrillation, CMBs ≥5 and with
SBI were independent predictive factors for the occurrence of
cerebrovascular events or vascular deaths in 1 year from onset.
DISCUSSION
We concluded the following results: (1) backward stepwise
multiple logistic regression analysis indicated that old age,
elevation of serum creatinine level and complicated with
leukoaraiosis were independent risk factors of CMBs; (2) the
prevalence of SBI was highest in HICH patients with CMBs;
(3) the existence and number of CMBs were relevant with
haematoma volumes in the lobes and deep brain; and (4) poorer
neurological functional recoveries in 3 months from onset were
observed in patients with CMBs≥5 than those without CMBs. In
addition, atrial fibrillation, CMBs ≥5 and SBI were observed as
independent predictive factors in clinical cerebrovascular events
or vascular deaths.
The prevalence of CMBs in primary or secondary
intracerebral hemorrhage patients is 50∼80% (Gregoire et al.,
2010). We discovered that the prevalence of CMBs in HICH
patients was 55%, and old age, elevation of serum creatinine
level and with leukoaraiosis played a role in independent risk
factors in CMB onset, which corresponded with previous
research studies (Poels et al., 2010; Ryu et al., 2012; Yamada
et al., 2012; Akoudad et al., 2013). Targeting the community
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FIGURE 1 | Distribution of average haematoma volumes of HICH in deep brain (basal ganglia and thalamus), infratentorial part (brainstem and
cerebellum) and lobes. Lobe hemorrhage patients with CMBs possessed more haematoma volumes than patients without CMBs; deep brain hemorrhage patients
with CMBs, however, possessed less haematoma volumes than those without CMBs, and the haematoma volumes in infratentorial hemorrhage patients with CMBs
were nearly equivalent to patients without CMBs. The data in the graph were expressed in the form of the average ± standard deviation (*P < 0.05).
TABLE 2 | Correlation analysis of CMBs number and 3-month functional recoveries of patients.
Unfavorable outcome, 3-month mRS score >2
Univariable analysis Multivariable analysis
OR 95% CI P-value OR 95% CI P-value
No CMB 1 (reference) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
1 CMB 2.67 0.23–30.80 0.432 10.34 0.62–172.14 0.103
2–4 CMBs 0.56 0.06–5.65 0.619 0.65 0.04–12.04 0.775
≥5 CMBs 11.28 2.72–46.76 <0.001 27.09 3.75–195.60 0.001
population, Poels et al., discovered that the prevalence of CMBs
increased with age. For instance, the prevalence of CMBs in a
population aged over 80 years was five times more than that in
the population aged between 45 and 50 years (Poels et al., 2010).
Ryu et al. found that among 909 cerebral infarction patients,
chronic kidney disease was independently relevant with CMBs
(Ryu et al., 2012). In addition, Yamada et al. revealed a close
relationship between the number of CMBs and periventricular
hyperintensity (PVH) or deep white matter hyperintensity
(DWMH) and regarded leukoaraiosis as an independent risk
factor of CMB severity (Yamada et al., 2012). In addition, in DWI
sequences, we found that approximately 11% of HICH patients
suffered from acute infarction in which the incidence was even
higher in patients with CMBs. Numerous recent research studies
have reported the existence of SBI in DWI sequences of ICH
patients (Okamoto et al., 2010; Prabhakaran et al., 2010; Kang
et al., 2012; Arsava et al., 2013). In addition, most of these
research studies showed that the onset of post-ICH DWI foci
was correlated with over acute decline of blood pressure, but
the underlying mechanism was still unclear. The CMBs, SBI
and leukoaraiosis all belonged to CSVD. The research studies
of Wardlaw et al. illustrated that CSVD was caused by brain
tissue hypoperfusion and brain parenchyma damage induced
by blood brain barrier destruction after vascular endothelial
injury and, interestingly, the various subtypes of interconnected
CSVD (Wardlaw et al., 2013a). However, due to the insidious
and undistinguishable onset, the clinical symptoms of CSVD
could only occur after a long progression. In addition, due to
hardness on the small vessels imaging, CSVD was then easily
ignored (Wardlaw et al., 2001).
CMBs are a type of intracerebral micro lesion with
hemorrhage tendency (Nighoghossian et al., 2002), and thus
when presented with CMBs, the probability of hemorrhage as
well as the haematoma volumes in patients are increased. Lee
et al. reported that lobe and putamen hemorrhage patients
with CMBs exhibited higher haematoma volumes than those
without CMBs and together present a positive correlation
relationship between haematoma volumes and CMB number
(Lee et al., 2006). Nevertheless, the haematoma volumes of
thalamus hemorrhage patients were not relevant to CMBs. They
proposed that CMBs might reflect the damaging degree of
the blood brain barrier. Thus, lobe and putamen hemorrhage
patients with CMBs had more haematoma volumes. As for the
thalamus, the hemorrhage might be restricted by surrounding
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FIGURE 2 | Ratio of clinical cerebrovascular events or vascular deaths 1 year after disease onsets in the two groups of patients (with/without CMBs)
using Kaplan-Meier analysis. Log-rank examination showed the existence of significant differences between the curves of two groups (P = 0.021).
FIGURE 3 | Distribution of modified Ranking Scale (mRS) score in 1-year follow-ups in HICH patients with or without CMBs. At 1 year after the onset, the
mRS scores of patients with CMBs shifted upwards.
tissues, and the frequency of intraventricular hemorrhage was
higher, which resulted in decreased bleeding volumes. In our
study, the results in lobe hemorrhage patients corresponded with
those in Lee’s research, and the haematoma volumes in patients
with CMBs were nearly twice as much as those in patients
without CMBs. However, in contrast with Lee’s reports, we found
decreased haematoma volumes in basal ganglia or thalamus
hemorrhage patients with CMBs and a negative correlation
relationship between haematoma volumes and the number of
CMBs. This difference might be due to the design of the study,
the groups recruited, the time between disease onset and CT
examination, the methods to measure the haematoma volumes
and the differences in MRI parameters. Thus, the effect on
haematoma volumes in different regions of CMBs deserves
further study.
CMBs may increase the incidence of primary or secondary
stroke and even mortality in patients (Nighoghossian et al., 2002;
Greenberg et al., 2004). In a population aged 70–82, the risk of
stroke related deaths in patients with CMBs ≥2 was six times
higher than that in patients without CMBs. When CMBs are
located in non-lobe regions, the risk of future cardiac death
was twice as high as those without CMBs (Altmann-Schneider
et al., 2011). However, differences were present regarding the
effects of CMBs on the 3-month functional prognosis after
intravenous thrombolysis in patients with acute ischaemic stroke
(Gratz et al., 2014; Turc et al., 2015; Yan et al., 2015). However,
few studies have been published examining the relationship
between CMB number and HICH prognosis. In addition, our
study found a close relevance between CMBs ≥5. With regard
to pathophysiology, CMBs reflected the bleeding tendency of
the brain, but during the 1-year follow-ups, we discovered that
the recurrent stroke in patients with CMBs were mostly due to
cerebral infarctions rather than ICH. Recently, controversies have
arisen indicating that patients with CMBs might demonstrate
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an increase on the following ICH (Linn, 2015). In addition,
some research studies showed that in patients with cerebral
amyloid angiopathy, only patients with CMBs located in the lobes
(specifically CMBs≥5) suffered from an increasing risk of future
ICH (Biffi et al., 2010). However, in our study, CMBs were mostly
located in the basal ganglia and thalamus. Thus, the location of
the CMBs may be potentially relevant in determining whether
CMBs could help predict the risk of future cerebral stroke.
However, there were some shortcomings in this study: (1) The
information of patients suffering from ICHwas not blinded to the
MRI readers. To reduce the deviations in CMBs quantification,
the radiologists did not know our hypothesis and the relationship
between the ICH and CMBs. In addition, the measurements
for haematoma volumes and CMBs number were performed
independently. (2) We excluded ICH patients caused by cerebral
amyloid angiopathy according to the Boston criteria and selected
patients with a history of hypertension. However, no brain
pathological examinations were performed, and our subjects
might thus be complicated with cerebral amyloid angiopathy,
which might affect the results. (3) Due to the rigidity of the
inclusion criteria, the number of enrolled patients was limited,
and further research studies withmore cases included are needed.
CONCLUSION
Overall, we proposed that elderly subjects, those with increased
serum creatinine levels and leukoaraiosis are independent risk
factors for the incidence of CMBs; furthermore, CMB patients
had a higher probability when presented with SBI. CMBs ≥5
affected neurological functional recoveries within 3 months
after disease onset in HICH patients. Patients with CMBs
≥5 or SBI might demonstrate increasing risks for clinical
cerebrovascular events or vascular deaths in 1 year. In the
future, if adequate attention and intervention is provided to
patients with CMBs proven by a SWI sequence but without
ICH, the incidence and bleeding volume of future ICH may be
reduced.
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